You just read:

Lilly Presents Positive Results for Taltz® (ixekizumab) in Pediatric Patients with Moderate to Severe Plaque Psoriasis at the 28th Annual European Academy of Dermatology and Venereology (EADV) Congress

News provided by

Eli Lilly and Company

Oct 12, 2019, 06:45 ET